• Altimmune (NASDAQ:ALT) and the U.S. FDA have reached agreement on the efficacy and safety measures to be evaluated in the company's phase 3 trials of obesity asset pemvidutide following an end-of-phase 2 meeting.
• The phase 3 program will encompass four randomized, double-blind, placebo-controlled trials lasting 60 weeks and enroll a total of 5,000 participants. Three dosage strength will be tested -- 1.2 mg, 1.8 mg, and 2.4 mg -- and the company said it is aiming for approval of all strengths.
• Each trial will enroll subjects with different comorbidities. For example, one will enroll individuals who are obese or overweight without diabetes, another in those with high LDL cholesterol, a third in those with elevated liver fat, and a fourth in an elderly population.
• Pemvidutide is considered a novel peptide-based GLP-1/glucagon dual receptor agonist.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。